Search results
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 1 day agoThe MASH space has heated up with the FDA approval of the first-ever treatment, a drug called...
Drugmakers in Medicare Price Talks Spent Less on R&D Than on Shareholders, Marketing, Overhead:...
The Fiscal Times via Yahoo Finance· 7 days agoThe report says that the eight companies — Johnson & Johnson, Amgen, AstraZeneca, Bristol Myers...
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Zacks via Yahoo Finance· 3 days agoBristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails...
Veeva and H&E Equipment Services have been highlighted as Zacks Bull and Bear of the Day
Zacks via Yahoo Finance· 4 days agoEssential Tech for Biotechs Veeva sells cloud-based offerings geared toward the pharmaceutical and...
123 New Jersey Students Graduate from Governor’s STEM Scholars
New Jersey Business Magazine· 2 days agoOn Saturday, May 11, 123 New Jersey high school and college students graduated from the Governor’s...
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
Zacks· 7 days agoAn FDA advisory committee meeting to discuss Eli Lilly’s (LLY Quick QuoteLLY - Free Report) Alzheimer’s candidate, donanemab, will be conducted on Jun 10. Merck’s (MRK Quick ...
Lilly's Once-Weekly Insulin Top-Line Results Show Benefit
Medscape· 18 hours agoEli Lilly has announced positive phase 3 topline results for its once-weekly insulin efsitora alfa...
Cinven to explore $3 billion sale of software maker Jaggaer, sources say
Reuters via Yahoo News· 3 days agoPrivate equity firm Cinven is preparing to explore a sale of Jaggaer that it hopes will value the maker of supply chain software at about $3 billion, including debt, according to people familiar ...
Why Lilly And Novo Nordisk Will Keep Dominating The Market For Blockbuster GLP-1 Drugs
Forbes· 1 day agoThe mass interest in GLP-1 drugs has led to a business boom for the two dominant pharmaceutical...
No Improvement in OS With Atezolizumab in Relapsing TNBC
Medscape· 18 hours agoEarly relapsing disease has again shown the limitations of immunotherapy in triple-negative breast...